Bradley J. Bloom

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo

Joel M. Kremer, Bradley J. Bloom, Ferdinand C. Breedveld et al. · Arthritis & Rheumatism · 2009 · 541 citations

Efficacy and Safety of CE-224,535, an Antagonist of P2X₇Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate

Thomas Stock, Bradley J. Bloom, Nathan Wei et al. · The Journal of Rheumatology · 2012 · 232 citations · Full text

Safety of Celecoxib in Patients With Ulcerative Colitis in Remission: A Randomized, Placebo-Controlled, Pilot Study

William J. Sandborn, William F. Stenson, Jørn Brynskov et al. · Clinical Gastroenterology and Hepatology · 2006 · 226 citations

Gastrointestinal Pharmacology, Gastroenterology, Ulcerative Colitis +2

Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial

William R. Lumry, H. Henry Li, Robyn J. Levy et al. · Annals of Allergy Asthma & Immunology · 2011 · 217 citations

Thrombosis, Cardiovascular Disease, Hereditary Angioedema +7

Detection of Borrelia burgdorferi DNA by Polymerase Chain Reaction in Cerebrospinal Fluid in Lyme Neuroborreliosis

James J. Nocton, Bradley J. Bloom, BARBARA J. RUTLEDGE et al. · The Journal of Infectious Diseases · 1996 · 170 citations

Engineering, Diagnosis, Pathology +17